ALKS
Alkermes plc
NASDAQ · Healthcare · Biotechnology · IE
$46.10
−1.66%Year over year
Reported trailing growth
- Revenue
- +10.8%
- EBITDA
- -51.6%
- EBIT
- -68.7%
- EPS
- -81.2%
- Free cash flow
- -53.8%
- Operating cash flow
- -51.8%
Forward estimates
Based on analyst estimates
- Revenue
- +12.5%
- EBITDA
- -29.3%
- EPS
- —
Three-year CAGR
- Revenue
- +9.9%
- EBITDA
- +76.9%
- EBIT
- -21.7%
- Net income
- -17.6%
- EPS
- -17.1%
- Free cash flow
- +16.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026